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Indeed, vasovagal syncope is often preceded by orthostatic stress, pooling of venous blood in the lower limbs, ineffective venoconstrictive responses, and decreased venous return and pre-load, which in turn reduces cardiac output, causing hypotension and reduced cerebral perfusion (6) (7) (8) . By increasing renal sodium reabsorption and expanding plasma volume, fludrocortisone counteracts this mechanism and blocks the physiological cascade leading to the vasovagal reflex. The mechanism of action is similar to that of saline infusion, which has also proved to be effective in short-term tilt-test studies (9,10).
WILL THE POST 2 TRIAL CHANGE CURRENT CLINICAL PRACTICE?
In the POST 2 trial, the clinical benefit of fludrocortisone therapy was modest and the risk of he has no relationships relevant to the contents of this paper to disclose. should not be used in patients with hypertension or heart failure.
WOULD THE BENEFIT BE GREATER IF FLUDROCORTISONE WERE PRESCRIBED FOR A SELECTED POPULATION?
Probably, yes. This is a typical study in which some patients benefit from the therapy, whereas others do not or must discontinue it because of side effects. Fludrocortisone is not for all patients with vasovagal syncope. Learning to identify responders will be crucial to acceptance of this therapy by the scientific community and will be the subject of 
